首页> 外文期刊>International Journal of Molecular Sciences >Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient
【24h】

Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient

机译:醋酸卡泊芬净一线疗法在非免疫功能低下患者中成功治疗肝曲霉病

获取原文
           

摘要

Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.
机译:在免疫功能低下的患者中,曲霉病仍然是威胁生命的并发症。但是,在极少数情况下,可以在非免疫功能低下的个体中观察到曲霉菌感染。我们报告了在相对完整的免疫状态下的慢性再生障碍性贫血患者中的一例肝曲霉病。对这种罕见病的治疗策略进行了广泛讨论,并在仔细考虑后应用醋酸卡泊芬净单药一线治疗。响应于抗真菌治疗,在临床和放射学方面取得了令人鼓舞的改善。我们的长期随访研究也显示了良好的预后。基于这一经验,我们建议醋酸卡泊芬净作为肝曲霉病的治疗计划的一线治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号